title: [Kinetics and dosimetry of monoclonal antibody MAb-170: evaluation of possibilities for intraperitoneal radioimmunotherapy].
abstract: The monoclonal antibody MAb-170 is directed against adenocarcinomas of different origin. Recent experience in radioimmunoscintigraphy revealed a positive uptake of this MAb in peritoneal metastases of ovarian carcinoma (FIGO III/IV).
  
  
  OBJECTIVE
  The present investigation should clarify the question whether this antibody could be of use in an adjuvant intraperitoneal radioimmunotherapy (RIT) in patients with minimal residual disease after first-look surgery.
  
  
  METHODS
  Four patients underwent intraperitoneal application of Tc-99m MAb-170. Subsequent quantitative whole-body scintigraphy, serum and urine sampling were performed for a 48 h period. In one case tumour tissue specimen were sampled during the first surgical procedure 15 h p.i..
  
  
  RESULTS
  The quantitative evaluation revealed no relevant accumulation in liver, spleen and bone marrow never exceeding 5% of the whole-body activity. The critical organs are the kidneys that showed 8 to 11% uptake at 24 h p.i.. The effective serum curve had a maximum at 24 h p.i., the second phase gave a elimination half-time of 53 h. Assuming the worst case, the mean dose to red bone marrow was 0.3 Gy/370 MBq injected dose (ID).
  
  
  CONCLUSIONS
  These results confirm that a RIT with Re-186 MAb-170 is feasible with activities of up to 3.7 GBq. A kit for labelling MAb-170 with Perrhenate is under investigation.
authors.affiliation: Abteilung für Nuklearmedizin, Universitätskliniken des Saarlandes, Homburg/Saar, Germany. racole@med-rz.uni-sb.de
authors.forename: C
authors.initials: C
authors.lastname: Alexander
authors.forename: M
authors.initials: M
authors.lastname: Holländer
authors.forename: W
authors.initials: W
authors.lastname: Schmidt
authors.forename: C M
authors.initials: CM
authors.lastname: Kirsch
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000532:radiotherapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001692:Biological Transport; D006801:Humans; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000000981:diagnostic imaging; D008875:Middle Aged; D015609:Organotechnetium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016499:Radioimmunotherapy / Q000379:methods*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C109623:technetium Tc 99m-monoclonal antibody-170H.82